Coxibs, science, and the public trust.

[1]  Thomas Brabant,et al.  The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. , 2005, Archives of internal medicine.

[2]  R. Stafford,et al.  National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. , 2005, Archives of internal medicine.

[3]  M. Egger,et al.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.

[4]  Sebastian Schneeweiss,et al.  Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.

[5]  J. Avorn,et al.  Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? , 2003, The American journal of medicine.

[6]  P. Duke,et al.  Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.

[7]  C Michael Stein,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[8]  H. Guess,et al.  Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. , 2002, Archives of internal medicine.

[9]  E. Rahme,et al.  Association between naproxen use and protection against acute myocardial infarction. , 2002, Archives of internal medicine.

[10]  Daniel H Solomon,et al.  Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. , 2002, Archives of internal medicine.

[11]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[12]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[13]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[14]  J. Concato,et al.  Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.

[15]  C. Stein,et al.  Making medicines safer--the need for an independent drug safety board. , 1998, The New England journal of medicine.